Payam A. Gammage

Payam A. Gammage

Auto-generated profile, based on publicly available information

Payam A. Gammage

Cancer Research UK Scotland Institute, Glasgow, UK

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Trends in Genetics
Verified
Journal Article
Open access
PGPayam A. Gammage
Payam A. Gammage
CMCarlos T Moraes
Carlos T Moraes
MMMichal Minczuk
Michal Minczuk
In recent years mitochondrial DNA (mtDNA) has transitioned to greater prominence across diverse areas of biology and medicine. The recognition of mitochondria as a major biochemical hub, contributions of mitochondrial dysfunction to various diseases, and several high-profile attempts to prevent hereditary mtDNA disease through mitochondrial replacement therapy have roused interest in the organellar genome. Subsequently, attempts to manipulate mtDNA have been galvanized, although with few robust advances and much controversy. Re-engineered protein-only nucleases such as mtZFN and mitoTALEN function effectively in mammalian mitochondria, although efficient delivery of nucleic acids into the organelle remains elusive. Such an achievement, in concert with a mitochondria-adapted CRISPR/Cas9 platform, could prompt a revolution in mitochondrial genome engineering and biological understanding. However, the existence of an endogenous mechanism for nucleic acid import into mammalian mitochondria, a prerequisite for mitochondrial CRISPR/Cas9 gene editing, remains controversial.

24 February 2014 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
PGPayam A Gammage
Payam A Gammage
JRJoanna Rorbach
Joanna Rorbach
AVAnna I Vincent
Anna I Vincent
EREdward J Rebar
Edward J Rebar
MMMichal Minczuk
Michal Minczuk
We designed and engineered mitochondrially targeted obligate heterodimeric zinc finger nucleases (mtZFNs) for site‐specific elimination of pathogenic human mitochondrial DNA (mtDNA). We used mtZFNs to target and cleave mtDNA harbouring the m.8993T>G point mutation associated with neuropathy, ataxia, retinitis pigmentosa (NARP) and the “common deletion” (CD), a 4977‐bp repeat‐flanked deletion associated with adult‐onset chronic progressive external ophthalmoplegia and, less frequently, Kearns‐Sayre and Pearson's marrow pancreas syndromes. Expression of mtZFNs led to a reduction in mutant mtDNA haplotype load, and subsequent repopulation of wild‐type mtDNA restored mitochondrial respiratory function in a CD cybrid cell model. This study constitutes proof‐of‐principle that, through heteroplasmy manipulation, delivery of site‐specific nuclease activity to mitochondria can alleviate a severe biochemical phenotype in primary mitochondrial disease arising from deleted mtDNA species.

24 September 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
PGPayam A. Gammage
Payam A. Gammage
Carlo ViscomiCarlo Viscomi
Carlo Viscomi
MSMarie-Lune Simard
Marie-Lune Simard
ACAna S. H. Costa
Ana S. H. Costa
EGEdoardo Gaude
Edoardo Gaude
MMMichal Minczuk
Michal Minczuk

1 February 2018 in Molecular Cell
Verified
Journal Article
Open access
EGEdoardo Gaude
Edoardo Gaude
CSChristina Schmidt
Christina Schmidt
PGPayam A. Gammage
Payam A. Gammage
ADAurelien Dugourd
Aurelien Dugourd
TBThomas Blacker
Thomas Blacker
CFChristian Frezza
Christian Frezza
The bioenergetics and molecular determinants of the metabolic response to mitochondrial dysfunction are incompletely understood, in part due to a lack of appropriate isogenic cellular models of primary mitochondrial defects. Here, we capitalize on a recently developed cell model with defined levels of m.8993T>G mutation heteroplasmy, mTUNE, to investigate the metabolic underpinnings of mitochondrial dysfunction. We found that impaired utilization of reduced nicotinamide adenine dinucleotide (NADH) by the mitochondrial respiratory chain leads to cytosolic reductive carboxylation of glutamine as a new mechanism for cytosol-confined NADH recycling supported by malate dehydrogenase 1 (MDH1). We also observed that increased glycolysis in cells with mitochondrial dysfunction is associated with increased cell migration in an MDH1-dependent fashion. Our results describe a novel link between glycolysis and mitochondrial dysfunction mediated by reductive carboxylation of glutamine.

30 April 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
VPViktoriya Peeva
Viktoriya Peeva
DBDaniel Blei
Daniel Blei
GTGenevieve Trombly
Genevieve Trombly
SCSarah Corsi
Sarah Corsi
MSMaciej J. Szukszto
Maciej J. Szukszto
Wolfram KunzWolfram Kunz
Wolfram Kunz
Emerging gene therapy approaches that aim to eliminate pathogenic mutations of mitochondrial DNA (mtDNA) rely on efficient degradation of linearized mtDNA, but the enzymatic machinery performing this task is presently unknown. Here, we show that, in cellular models of restriction endonuclease-induced mtDNA double-strand breaks, linear mtDNA is eliminated within hours by exonucleolytic activities. Inactivation of the mitochondrial 5′-3′exonuclease MGME1, elimination of the 3′-5′exonuclease activity of the mitochondrial DNA polymerase POLG by introducing the p.D274A mutation, or knockdown of the mitochondrial DNA helicase TWNK leads to severe impediment of mtDNA degradation. We do not observe similar effects when inactivating other known mitochondrial nucleases (EXOG, APEX2, ENDOG, FEN1, DNA2, MRE11, or RBBP8). Our data suggest that rapid degradation of linearized mtDNA is performed by the same machinery that is responsible for mtDNA replication, thus proposing novel roles for the participating enzymes POLG, TWNK, and MGME1.

27 July 2016 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
PGPayam A. Gammage
Payam A. Gammage
EGEdoardo Gaude
Edoardo Gaude
LHLindsey Van Haute
Lindsey Van Haute
PRPedro Rebelo-Guiomar
Pedro Rebelo-Guiomar
CJChristopher B. Jackson
Christopher B. Jackson
MMMichal Minczuk
Michal Minczuk
Mitochondrial diseases are frequently associated with mutations in mitochondrial DNA (mtDNA). In most cases, mutant and wild-type mtDNAs coexist, resulting in heteroplasmy. The selective elimination of mutant mtDNA, and consequent enrichment of wild-type mtDNA, can rescue pathological phenotypes in heteroplasmic cells. Use of the mitochondrially targeted zinc finger-nuclease (mtZFN) results in degradation of mutant mtDNA through site-specific DNA cleavage. Here, we describe a substantial enhancement of our previous mtZFN-based approaches to targeting mtDNA, allowing near-complete directional shifts of mtDNA heteroplasmy, either by iterative treatment or through finely controlled expression of mtZFN, which limits off-target catalysis and undesired mtDNA copy number depletion. To demonstrate the utility of this improved approach, we generated an isogenic distribution of heteroplasmic cells with variable mtDNA mutant level from the same parental source without clonal selection. Analysis of these populations demonstrated an altered metabolic signature in cells harbouring decreased levels of mutant m.8993T>G mtDNA, associated with neuropathy, ataxia, and retinitis pigmentosa (NARP). We conclude that mtZFN-based approaches offer means for mtDNA heteroplasmy manipulation in basic research, and may provide a strategy for therapeutic intervention in selected mitochondrial diseases.